Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FLT3 | P36888 | 10/20 | 0.74 |
| ▸ | CCNT1 | O60563 | 5/20 | 0.46 |
| ▸ | TTK | P33981 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
| ▸ | BACE1 | P56817 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12527183 | 1.00 | FLT3 (0.74) | FLT3CCNT1TTKADORA3BRD4 | |
| SCHEMBL12527715 | 0.93 | FLT3 (0.64) | FLT3TTKADORA3ACHEBACE1 | |
| SCHEMBL12272831 | 0.93 | FLT3 (0.64) | FLT3TTKADORA3ACHEBACE1 | |
| SCHEMBL12272704 | 0.93 | FLT3 (0.74) | FLT3CCNT1TTKADORA3 | |
| SCHEMBL12527196 | 0.93 | FLT3 (0.74) | FLT3CCNT1TTKADORA3 | |
| SCHEMBL12522788 | 0.92 | FLT3 (0.72) | FLT3CCNT1TTKACHE | |
| SCHEMBL12272664 | 0.92 | FLT3 (0.72) | FLT3CCNT1TTKACHE | |
| SCHEMBL12522709 | 0.88 | FLT3 (0.58) | FLT3CCNT1TTKADORA3 | |
| SCHEMBL12272885 | 0.88 | FLT3 (0.58) | FLT3CCNT1TTKADORA3 | |
| SCHEMBL12522706 | 0.87 | FLT3 (0.59) | FLT3CCNT1TTKADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2686319-B1 | IMIDAZO PYRAZINES | HOFFMANN LA ROCHE (CH) | 2016-07-13 | — | — | EP | disclosed |
| US-8673905-B2 | Imidazo pyrazines | HOFFMANN-LA ROCHE INC. (US) | 2014-03-18 | — | — | US | disclosed |
| EP-2686319-A1 | IMIDAZO PYRAZINES | F.HOFFMANN-LA ROCHE AG (CH) | 2014-01-22 | — | — | EP | disclosed |
| US-20120238564-A1 | IMIDAZO PYRAZINES | LUK KIN-CHUN (US) | 2012-09-20 | — | — | US | disclosed |
| WO-2012123470-A1 | IMIDAZO PYRAZINES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120238564-A1 | IMIDAZO PYRAZINES | THPO, MCL1, IKZF3 | FLT3 5/4885CCNT1 4130/4885TTK 2825/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.